For patients receiving medica- tions other than amiodarone, catheter abla- tion did not reduce the risk of ICD shocks or VT storm compared with switching to amioda- rone. Although recurrent VT after catheter abla- tion is associated with increased mortality,S7.1.3-9 whether mortality is reduced by catheter abla- tion has not been established. Procedural com- plications occur in approximately 6% of patients, most of which are related to vascular access but stroke, tamponade, and atrioventricular block can occur. Procedure mortality is <1% in experi- Sustained monomorphic VT often occurs as occasional isolated episodes in patients with prior MI. Several nonrandomized studies have shown that catheter ablation reduces recurrent VT or ICD shocks.S7.1.3-5,S7.1.3-7,S7.1.3-8 A meta-anal- ysis of 5 VT ablation studiesS7.1.3-5 reported that VT recurred in 35% of patients after catheter ablation compared with 55% on antiarrhythmic medications. In a multicenter study of catheter for patients with 3 episodes of sustained VT in the prior 6 months, 53% were free from recurrent VT at 6 months follow-up; the median number of VT episodes was reduced from 11.5 to 0. Superiority of ablation over es- calating medication therapy was shown in the composite endpoint of death, VT storm, or ICD shocks by the VANISH trial.S7.1.3-4 3. Patients with prior MI who develop sustained monomorphic VT often have recurrent episodes. The VTACH (Ventricular Tachycardia Ablation in Addition to Implantable Defibrillators in Coronary Heart Disease) trialS7.1.3-11 randomized patients undergoing ICD implantation for stable sustained monomorphic VT, who had not failed antiarrhyth- mic medication therapy, to catheter ablation ver- sus ICD implantation alone. At 2 years, any VT had recurred in 53% of the ablation group and 71% of the control group. 